Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents of $130.3M in Q2 FY2026
Q2 FY2026 cash & equivalents was $130.3M.
Context
- Cash & equivalents amounted to 10.8% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 160.27M USD
- Year-over-year change
- —
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 160.27M | — |
Cash & Equivalents vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's Jun 2026 cash & equivalents of $130.3M is the 4th highest of the 10 companies compared; the peer median is $98.09M.
- Cash & equivalents amounts to 10.8% of total assets for KLRA, versus a peer median of 60.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $424.15M | -24.8% | +1.6% | 60.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M | -6.1% | +89.8% | 60.8% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M | -27.5% | +46.0% | 32.3% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $130.3M | — | — | 10.8% |
| Jun 2026 | $125.75M | +271.2% | +65.4% | 24.1% | |
| Mar 2026 | $98.09M | +215.8% | +94.3% | 99.3% | |
| Mar 2026 | $97.6M | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $63.17M | +50.0% | +18.3% | 63.6% | |
| Mar 2026 | $44.69M | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $13.2M | -82.3% | +4.3% | 4.9% | |
| Peer median (excluding KLRA) | $98.09M | +24.6% | +18.3% | 60.2% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2025 Dec 2025 |
|---|---|
| Cash & Equivalents | 160.27M |
| Short-term Investments | 385.79M |
| Net Receivables | 2.73M |
| Inventory | 0 |
| Other Current Assets | 1.23M |
| Total Current Assets | 557.54M |
| Property, Plant & Equipment (Net) | 12.42M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-term Investments | 106.67M |
| Tax Assets | 0 |
| Other Non-current Assets | 15.67M |
| Total Non-current Assets | 134.76M |
| Total Assets | 692.29M |
| Account Payables | 7.53M |
| Short-term Debt | 0 |
| Tax Payables | 0 |
| Deferred Revenue | 0 |
| Other Current Liabilities | 9.97M |
| Total Current Liabilities | 46.41M |
| Long-term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Deferred Revenue (Non-current) | 0 |
| Other Non-current Liabilities | 992.63M |
| Total Non-current Liabilities | 1B |
| Total Liabilities | 1.05B |
| Common Stock | 0 |
| Retained Earnings | (368.67M) |
| Accumulated OCI | 229K |
| Other Stockholders Equity | 0 |
| Minority Interest | 0 |
| Total Equity | (356.46M) |
| Total Debt | 10.75M |
| Net Debt | (149.51M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.